The importance of prevention trials in Alzheimer’s disease with Randall Bateman

Written by Sharon Salt, Editor

Clinical trials for Alzheimer’s disease have predominantly focused on individuals who have already developed symptoms. However, in the last few years, researchers have initiated trials at a much earlier stage of the disease course when brain pathology hasn’t yet appeared (primary prevention trials). At the Wolfson Closing Symposium (19 June 2019, University College London, UK), we spoke with Randall Bateman (Washington University, MO, USA) to discover more about these prevention trials in Alzheimer’s disease, including what primary prevention trials are telling us so far and what the main challenges surrounding such trials are. Interview questions on prevention trials in Alzheimer’s...

To view this content, please register now for access

It's completely free